{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=102", "query": { "condition": "Advanced Malignancy", "page": 102 }, "page_size": 10 }, "pagination": { "page": 102, "page_size": 10, "total_count": 9820, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=103&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=101&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T14:59:14.051Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01149434", "title": "Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Neuroendocrine", "Ovarian Cancer", "Colon Cancer" ], "interventions": [ { "name": "JI-101", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-09", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-10-06", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149434" }, { "nct_id": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Salvage Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-04-24", "completion_date": "2033-02-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 115, "location_summary": "Tucson, Arizona • Irvine, California • Los Angeles, California + 85 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195734" }, { "nct_id": "NCT04164199", "title": "Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Pamiparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "BAT1706", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "BGB-15025", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "BGB-A445", "type": "DRUG" }, { "name": "Surzebiclimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "LBL-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2019-12-19", "completion_date": "2026-05-23", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 4, "location_summary": "Miami, Florida • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164199" }, { "nct_id": "NCT06062498", "title": "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen-receptor-positive Breast Cancer", "HER2/Neu-Negative Breast Cancer", "Advanced Breast Cancerv", "Metastatic Breast Cancer" ], "interventions": [ { "name": "elacestrant, palbociclib, abemaciclib, ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2023-09-29", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 3, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06062498" }, { "nct_id": "NCT05640765", "title": "BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Lung Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Health Promotion and Education", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 55, "start_date": "2021-02-03", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05640765" }, { "nct_id": "NCT00327600", "title": "Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "imexon", "type": "DRUG" }, { "name": "DTIC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AmpliMed Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2010-09-15", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00327600" }, { "nct_id": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Unresectable Metastatic Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 654, "start_date": "2023-05-08", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 30, "location_summary": "Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840211" }, { "nct_id": "NCT04005144", "title": "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Gene Rearrangement", "Lung Non-Small Cell Carcinoma", "Progressive Disease", "ROS1 Gene Rearrangement", "Stage IIIB Lung Cancer", "Stage IIIC Lung Cancer", "Stage IV Lung Cancer", "Stage IVA Lung Cancer", "Stage IVB Lung Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Brigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-02-25", "completion_date": "2022-10-01", "has_results": false, "last_update_posted_date": "2022-10-17", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005144" }, { "nct_id": "NCT00390234", "title": "Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Female Reproductive Cancer", "Ovarian Carcinosarcoma", "Ovarian Sarcoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Uterine Sarcoma", "Stage III Ovarian Epithelial Cancer", "Stage III Uterine Sarcoma", "Stage IV Ovarian Epithelial Cancer", "Stage IV Uterine Sarcoma", "Uterine Carcinosarcoma", "Uterine Leiomyosarcoma" ], "interventions": [ { "name": "ziv-aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2006-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 8, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390234" }, { "nct_id": "NCT00604409", "title": "Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Liver Cancer" ], "interventions": [ { "name": "SIRT", "type": "RADIATION" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2006-04", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-11-11T14:59:14.051Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00604409" } ] }